Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection
Authors:
Open Access
- 27 September 2013
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 455 (2) , 133-147
Abstract
The specificity of RNAi and its ability to silence ‘undruggable’ targets has made inhibition of gene expression in T-cells with siRNAs an attractive potential therapeutic strategy for the treatment of inflammatory disease, cancer and infection. However, delivery of siRNAs into primary T-cells represents a major hurdle to their use as potential therapeutic agents. Recent advances in siRNA delivery through the use of electroporation/nucleofection, viral vectors, peptides/proteins, nanoparticles, aptamers and other agents have now enabled efficient gene silencing in primary T-cells both in vitro and in vivo. Overcoming such barriers in siRNA delivery offers exciting new prospects for directly targeting T-cells systemically with siRNAs, or adoptively transferring T-cells back into patients following ex vivo manipulation with siRNAs. In the present review, we outline the challenges in delivering siRNAs into primary T-cells and discuss the mechanism and therapeutic opportunities of each delivery method. We emphasize studies that have exploited RNAi-mediated gene silencing in T-cells for the treatment of inflammatory disease, cancer and infection using mouse models. We also discuss the potential therapeutic benefits of manipulating T-cells using siRNAs for the treatment of human diseases.Keywords
This publication has 184 references indexed in Scilit:
- Short Hairpin RNA-Mediated Gene Silencing2012
- RNA-Based Therapeutics: Current Progress and Future ProspectsChemistry & Biology, 2012
- Treating cancer with genetically engineered T cellsTrends in Biotechnology, 2011
- PKC-θ function at the immunological synapse: prospects for therapeutic targetingTrends in Immunology, 2011
- Inhibition of T‐cell activation by syndecan‐4 is mediated by CD148 through protein tyrosine phosphatase activityEuropean Journal of Immunology, 2011
- Integration profile of retroviral vector in gene therapy treated patients is cell‐specific according to gene expression and chromatin conformation of target cellEMBO Molecular Medicine, 2011
- Dysfunctional memory CD8+ T cells after priming in the absence of the cell cycle regulator E2F4Cellular Immunology, 2009
- Lentiviral delivery of short hairpin RNAsAdvanced Drug Delivery Reviews, 2009
- Cell Type-Specific Targeting with Surface-Engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic MoleculePharmaceutical Research, 2009
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008